Cholesterol-lowering medicines that clearly cut heart attacks, strokes, and deaths in people who already have heart or artery disease; in those without it, benefit is smaller and hinges on personal risk. Main trade-offs are a modest rise in diabetes among the metabolically vulnerable and mostly expectation-driven muscle complaints. Truly dangerous reactions are rare. (Full Review)

Protocol

Intensity

Matched to risk

Moderate (atorvastatin 10–20 mg, rosuvastatin 5–10 mg) to high (atorvastatin 40–80 mg, rosuvastatin 20–40 mg)

Timing

Once daily

Short-acting statins in the evening; long-acting (atorvastatin, rosuvastatin, pitavastatin) at any consistent time

Dosing

Single daily dose

Splitting not standard; intermittent every-other-day dosing of long-acting statins only as a tolerability strategy

Time to effect

LDL lowering

2–4 weeks

Measurable reduction; steady state by 4–6 weeks

Cardiovascular benefit

Months to years

Event reduction accrues with continued use

Plaque regression

1.5–2 years

Modest shrinkage with high-intensity therapy

Benefits

High: Prevention of repeat cardiovascular events; reduction of atherogenic cholesterol; prevention of first cardiovascular events in higher-risk adults

Medium: Reduction in all-cause mortality; reduction in ischemic stroke; plaque stabilization and regression

Low: Reduction of vascular inflammation

Speculative: Possible reduction in dementia risk; possible reduction in venous thromboembolism

Contraindications

Pregnancy and breastfeeding

Active liver disease (transaminases persistently >3× upper limit of normal)

Prior serious statin-induced muscle injury

Key Interactions

Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir, cyclosporine)

Fibrates, especially gemfibrozil

Amiodarone, verapamil, diltiazem (simvastatin dose caps)

High-dose niacin

Red yeast rice

St. John's wort

Grapefruit juice

Risk & Side Effects

High: New-onset type 2 diabetes; statin-associated muscle symptoms; liver enzyme elevations

Medium: Hemorrhagic stroke

Low: Rhabdomyolysis; cognitive complaints

Speculative: Tendon and connective tissue complaints

Monitoring

Marker	Target	Why
ApoB	<80 mg/dL (high-risk <60 mg/dL)	Best marker of atherogenic particle number and the true drug target
LDL cholesterol	<100 mg/dL (high-risk <70 mg/dL)	Primary treated lipid; tracks intensity of therapy
Lipoprotein(a)	<30 mg/dL (<75 nmol/L)	Inherited risk particle not lowered by statins
ALT / AST	ALT <25 (women) / <30 (men) U/L	Detect hepatotoxicity
Creatine kinase	Within normal; symptom-triggered	Detect muscle injury/myopathy
HbA1c	<5.4%	Monitor for new-onset diabetes
High-sensitivity CRP	<1.0 mg/L	Track residual inflammatory risk

Cadence: Lipids at 6–12 weeks after starting or dose change, then every 6–12 months; glucose/HbA1c every 6–12 months in those at metabolic risk; liver enzymes and creatine kinase as prompted by symptoms

Qualitative Assessment

Absence of new or worsening muscle aches, cramps, or weakness
Stable energy and exercise tolerance
Subjective cognitive clarity
Overall tolerability and absence of digestive upset

Statins for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment